5AM Ventures

CAMP4 Therapeutics Corporation is a bioinformatics company based in Cambridge, Massachusetts, founded in 2015. The company specializes in gene regulation circuitry, utilizing a 4-D gene circuitry platform to codify the activation of the over 24,000 genes in the human body into a set of combinatorial rules. This approach allows CAMP4 to manipulate gene production through existing cellular signaling pathways, directly addressing the fundamental causes of diseases. By leveraging machine learning algorithms, the platform simplifies the drug discovery process, enabling the identification of druggable targets and facilitating a quicker and less risky path to developing new medicines. This innovative methodology significantly accelerates the initiation of disease treatment, ultimately benefiting patients by reducing the time required to bring new therapies to market.

Magnetic Insight, Inc. specializes in magnetic particle imaging (MPI), a novel imaging modality that detects iron oxide nanoparticle tracers using time-varying magnetic fields. The company has developed several key products, including the MOMENTUM imager, a pre-clinical MPI solution that produces detailed images through advanced reconstruction techniques, and VivoTrax, a nanoparticle designed for cell tracking and as a blood pool agent in pre-clinical studies. Additionally, the company offers Hyper, a module for localized magnetic hyperthermia, and Relax, which focuses on particle relaxometry. Founded in 2012 and based in Alameda, California, Magnetic Insight is dedicated to enhancing preclinical diagnostics and research by enabling quantitative cell tracking, imaging vascular functions, and detecting metastatic tumors, thereby addressing significant challenges in clinical and translational research.

Dianthus Therapeutics is a biotech company operating in stealth mode. It was founded in 2019 and is based in Waltham, Massachusetts.

Radionetics Oncology is a biopharmaceutical company dedicated to the discovery and development of innovative radiotherapeutics aimed at treating various oncology indications. The company specializes in creating non-peptide and small molecule agents that facilitate the targeted delivery of therapeutic radioisotopes to solid tumors. This focus positions Radionetics Oncology to address the growing need for advanced treatment options in oncology, enhancing the capabilities of medical professionals in managing cancer.

Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, that specializes in the development of liquid and tissue biopsy analysis platforms aimed at the detection of rare cells. Founded in 2009, RareCyte focuses on providing innovative technologies for the Life Sciences research, drug development, and diagnostic markets. The company offers a range of products, including sample preparation systems, staining kits, and automated fluorescence microscopy instruments. Its AccuCyte system is particularly notable for enabling the unbiased discovery and isolation of circulating tumor cells and circulating endothelial cells from whole blood. RareCyte's technologies are designed to address complex challenges in cancer and cardiovascular disease research, facilitating advancements in precision medicine and non-invasive prenatal testing.

Neurogastrx, Inc. is a venture-stage biopharmaceutical company focused on developing innovative therapies for gastrointestinal disorders. Established in 2017 and located in Campbell, California, the company aims to address the unmet medical needs associated with functional and motility disorders of the gastrointestinal tract. One of its key products, NG101, is designed to enhance gastric motility while also possessing antiemetic properties. Neurogastrx's specialty therapies target the enteric nervous system, addressing issues related to gut contractions, sensation, and the brain-gut axis, ultimately striving to alleviate the burden of these disorders on patients and the healthcare system.

TMRW Life Sciences is a developer of a cryo-storage platform intended to improve the success rates of assisted reproductive technology. The company's platform offers an in-clinic robotic storage system and a fully digital chain of custody from clinic to offsite longterm storage, continuous remote and local monitoring and electronically integrated processes characterized by digital health signals received from every oocyte and embryo daily, enabling clients to streamline embryology lab operations, eliminate manual steps and integrates digital quality control.

CAMP4 Therapeutics Corporation is a bioinformatics company based in Cambridge, Massachusetts, founded in 2015. The company specializes in gene regulation circuitry, utilizing a 4-D gene circuitry platform to codify the activation of the over 24,000 genes in the human body into a set of combinatorial rules. This approach allows CAMP4 to manipulate gene production through existing cellular signaling pathways, directly addressing the fundamental causes of diseases. By leveraging machine learning algorithms, the platform simplifies the drug discovery process, enabling the identification of druggable targets and facilitating a quicker and less risky path to developing new medicines. This innovative methodology significantly accelerates the initiation of disease treatment, ultimately benefiting patients by reducing the time required to bring new therapies to market.

Soteria Biotherapeutics, Inc., founded in 2018 and based in San Francisco, California, specializes in the development of innovative immunotherapies for cancer treatment. The company is focused on creating next-generation conditionally active bispecific T-cell engaging antibodies aimed at addressing solid tumors. Utilizing its proprietary T-LITE™ platform, Soteria enables the small molecule-dependent activation of these bispecific antibody therapies. This approach allows for safer and more effective treatments, characterized by pulsatile activity that minimizes side effects and permits higher dosing levels for patients. Through its advancements, Soteria Biotherapeutics strives to improve the therapeutic options available for cancer patients.

Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.

Enliven Therapeutics is a clinical-stage precision oncology company dedicated to the discovery and development of innovative small molecule therapies aimed at enhancing patient outcomes. The company focuses on addressing critical challenges in cancer treatment, such as tolerability, combinability, resistance, and disease progression, particularly in the context of brain metastases. Enliven's lead product candidates include ELVN-001, a selective small molecule kinase inhibitor targeting the BCR-ABL gene fusion associated with chronic myeloid leukemia, and ELVN-002, an irreversible HER2 inhibitor designed to penetrate the central nervous system and target both wild type HER2 and related variants. Through its advanced discovery process, Enliven Therapeutics aims to create first-in-class therapies that improve the quality of life for patients facing cancer.

Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts.

Inipharm Inc. is a biopharmaceutical company based in Bellevue, Washington, established in 2018. The company specializes in discovering and developing therapies for severe liver diseases, particularly nonalcoholic steatohepatitis (NASH). Inipharm focuses on small-molecule drugs that target HSD17B13, a gene linked to various liver conditions. By modulating this gene's activity, Inipharm aims to reduce liver damage, inflammation, and fibrosis, addressing significant unmet medical needs in the treatment of liver diseases.

Escient Pharmaceuticals, Inc., a biotechnology company, develops and manufactures G protein-coupled receptor (GPCR)-targeted drugs for treating neuro-immuno-inflammatory and autoreactive diseases. The company focuses on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-Protein Receptors (Mrgprs) for neuro-immuno-inflammatory and autoreactive diseases. Escient Pharmaceuticals, Inc. was formerly known as Mas Therapeutics, Inc. The company was founded in 2017 and is based in San Diego, California.

Nido Biosciences, Inc., founded in 2018 and based in Boston, Massachusetts, operates in the healthcare services sector. The company specializes in biotechnology and personal health, aiming to innovate within these fields. Currently in stealth mode, Nido Biosciences is focused on developing solutions that address unmet needs in healthcare and personal health management.

Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Artiva Biotherapeutics, Inc., a biotech company, develops and manufactures cellular immunotherapies for cancer patients. The company offers a pipeline of off-the-shelf, allogeneic natural killer (NK) cell therapies for the treatment of hematologic cancers or solid tumors. The company’s products target CD20 and CD19 in B-cell lymphomas and HER2 in various solid tumors. The company was founded in 2019 and is headquartered in San Diego, California. Artiva Biotherapeutics, Inc. operates as a subsidiary of Green Cross Holdings Corporation.

NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.

Novome Biotechnologies, Inc. is a biotechnology company based in South San Francisco, California, that specializes in engineering bacteria from the human gut to address chronic diseases. Founded in 2015, the company has developed a platform for the controlled colonization of the gut with genetically engineered bacteria, known as Genetically Engineered Microbial Medicines (GEMMs). This innovative approach allows for sustained therapeutic interventions through the precise delivery of microbial activities. Novome's lead preclinical program targets hyperoxaluria by creating a therapeutic strain of bacteria aimed at degrading oxalate to help prevent kidney stone formation. The company is also expanding its synthetic biology platform to explore additional therapeutic applications.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, that specializes in the development of liquid and tissue biopsy analysis platforms aimed at the detection of rare cells. Founded in 2009, RareCyte focuses on providing innovative technologies for the Life Sciences research, drug development, and diagnostic markets. The company offers a range of products, including sample preparation systems, staining kits, and automated fluorescence microscopy instruments. Its AccuCyte system is particularly notable for enabling the unbiased discovery and isolation of circulating tumor cells and circulating endothelial cells from whole blood. RareCyte's technologies are designed to address complex challenges in cancer and cardiovascular disease research, facilitating advancements in precision medicine and non-invasive prenatal testing.

TMRW Life Sciences is a developer of a cryo-storage platform intended to improve the success rates of assisted reproductive technology. The company's platform offers an in-clinic robotic storage system and a fully digital chain of custody from clinic to offsite longterm storage, continuous remote and local monitoring and electronically integrated processes characterized by digital health signals received from every oocyte and embryo daily, enabling clients to streamline embryology lab operations, eliminate manual steps and integrates digital quality control.

Wildcat Discovery Technologies, Inc. is a materials discovery company based in San Diego, California, founded in 2006. The company specializes in the discovery and development of advanced materials for clean tech energy applications, particularly focusing on rechargeable and primary batteries. Wildcat employs unique high-throughput synthesis and testing platforms that allow for the rapid exploration and evaluation of thousands of materials weekly. Its product offerings include metal alloys, ceramics, and materials for lithium-ion battery electrodes, hydrogen storage, and carbon capture, among others. The company also engages in collaborative development projects, partnering with industry leaders across the battery supply chain, including material suppliers and manufacturers in sectors such as automotive and electronics. Wildcat's goal is to enhance material performance, safety, and sustainability, contributing to the advancement of energy technologies.

Nido Biosciences, Inc., founded in 2018 and based in Boston, Massachusetts, operates in the healthcare services sector. The company specializes in biotechnology and personal health, aiming to innovate within these fields. Currently in stealth mode, Nido Biosciences is focused on developing solutions that address unmet needs in healthcare and personal health management.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.

Purigen Biosystems' innovative products offer a truly transformative solution for DNA and RNA purification. Our proprietary approach uses isotachophoresis to separate nucleic acids freely in solution without binding or stripping from a physical surface. Because of this, our technology is agnostic to nucleic acid size or sequence and delivers unbiased results ― even from the more challenging sample types like FFPE tissue or low cell counts. Our Ionic Purification System and Kits combine to provide researchers with a fast, efficient and effective alternative for automated nucleic acid purification.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, a novel aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its promising clinical candidates, CinCor Pharma seeks to gain marketing approval for innovative therapies that can effectively address unmet medical needs in these critical areas of health.

Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Kinestral Technologies, Inc. specializes in manufacturing smart-tinting glass, branded as Halio, for both commercial and residential applications. Halio glass can transition from clear to tinted or dark, either automatically or on command, enhancing architectural design by providing versatile solutions for windows, walls, and skylights. This technology offers significant advantages over traditional electrochromic glass, including faster tinting, uniform coloration, and a natural appearance. Kinestral also provides a range of supporting products, such as the Halio Tint Selector, which allows localized control of window tinting, and Halio Cloud, an interface for integrating window operations with building automation systems. Founded in 2010 and headquartered in Hayward, California, Kinestral has established a strategic partnership with Asahi Glass Co., Ltd. Its advanced manufacturing techniques ensure reliable production and timely delivery for projects worldwide, ultimately aiming to improve energy efficiency and comfort in indoor environments.

Pear Therapeutics, Inc. focuses on developing and delivering clinically validated software-based therapeutics aimed at treating behavioral health disorders, including psychiatric and neurologic conditions. The company creates digital therapies for severe conditions such as addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and chronic insomnia. Its key products include mobile digital therapies that incentivize patients for completing treatment modules, reSET for substance use disorder, reSET-O for opioid use disorder, and Somryst for insomnia. Additionally, Pear Therapeutics offers PearConnect, a comprehensive patient services center that provides support for patients throughout their treatment journey, connects healthcare providers to resources, and assists insurance companies with claims processing. Founded in 2013, Pear Therapeutics is headquartered in Boston, Massachusetts, with an additional office in San Francisco, California.

Cabaletta Bio is a clinical-stage biotechnology company dedicated to developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Utilizing its proprietary technology, the company focuses on chimeric autoantibody receptor (CAAR) T cells, which are engineered to selectively target and eliminate pathogenic B cells responsible for producing harmful autoantibodies while preserving healthy B cells. The company’s lead product candidate, DSG3-CAART, is currently undergoing a Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, a debilitating autoimmune skin disease, as well as Hemophilia A with Factor VIII alloantibodies. Cabaletta's pipeline also includes MuSK-CAART, aimed at treating certain patients with myasthenia gravis, and FVIII-CAART and DSG3/1-CAART, both in earlier stages of development for different autoimmune conditions. Founded in 2017 and headquartered in Philadelphia, Cabaletta Bio has established collaborations with the University of Pennsylvania and The Regents of the University of California to further its research efforts.

Enliven Therapeutics is a clinical-stage precision oncology company dedicated to the discovery and development of innovative small molecule therapies aimed at enhancing patient outcomes. The company focuses on addressing critical challenges in cancer treatment, such as tolerability, combinability, resistance, and disease progression, particularly in the context of brain metastases. Enliven's lead product candidates include ELVN-001, a selective small molecule kinase inhibitor targeting the BCR-ABL gene fusion associated with chronic myeloid leukemia, and ELVN-002, an irreversible HER2 inhibitor designed to penetrate the central nervous system and target both wild type HER2 and related variants. Through its advanced discovery process, Enliven Therapeutics aims to create first-in-class therapies that improve the quality of life for patients facing cancer.

Entrada Therapeutics, Inc., a biotechnology company, engages in the treatment of diseases through the intracellular delivery of biologic. The company enables intracellular delivery of proteins, peptides, and nucleic acids and allows development of programs across intracellular target classes. Its Intracellular enzyme replacement therapy (IC-ERT) is a medical treatment that corrects an enzyme deficiency in the cell, Protein-Protein Interaction Inhibitors. The company was founded in 2016 and is based in Boston, Massachusetts.

Magnetic Insight, Inc. specializes in magnetic particle imaging (MPI), a novel imaging modality that detects iron oxide nanoparticle tracers using time-varying magnetic fields. The company has developed several key products, including the MOMENTUM imager, a pre-clinical MPI solution that produces detailed images through advanced reconstruction techniques, and VivoTrax, a nanoparticle designed for cell tracking and as a blood pool agent in pre-clinical studies. Additionally, the company offers Hyper, a module for localized magnetic hyperthermia, and Relax, which focuses on particle relaxometry. Founded in 2012 and based in Alameda, California, Magnetic Insight is dedicated to enhancing preclinical diagnostics and research by enabling quantitative cell tracking, imaging vascular functions, and detecting metastatic tumors, thereby addressing significant challenges in clinical and translational research.

Impel NeuroPharma is a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier(BBB) using direct nose-to-brain delivery. It is focused on developing transformative therapies that unlock the full potential of therapeutic molecules for people living with CNS disorders with high unmet medical needs. The company was founded in 2008 and is headquartered in Seattle, Washington.

Aprea Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing cancer therapeutics that target the mutant p53 tumor suppressor protein. The lead product candidate, APR-246, is a first-in-class small molecule p53 reactivator currently in late-stage clinical development for hematologic malignancies, specifically myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006 and headquartered in Boston, Massachusetts, Aprea aims to address significant unmet medical needs in cancer treatment through innovative therapies. The company is primarily backed by KDev Investments AB and other stakeholders, including Östersjöstiftelsen and Praktikerinvest, reflecting a strong investment foundation for its research and development efforts.

Cabaletta Bio is a clinical-stage biotechnology company dedicated to developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Utilizing its proprietary technology, the company focuses on chimeric autoantibody receptor (CAAR) T cells, which are engineered to selectively target and eliminate pathogenic B cells responsible for producing harmful autoantibodies while preserving healthy B cells. The company’s lead product candidate, DSG3-CAART, is currently undergoing a Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, a debilitating autoimmune skin disease, as well as Hemophilia A with Factor VIII alloantibodies. Cabaletta's pipeline also includes MuSK-CAART, aimed at treating certain patients with myasthenia gravis, and FVIII-CAART and DSG3/1-CAART, both in earlier stages of development for different autoimmune conditions. Founded in 2017 and headquartered in Philadelphia, Cabaletta Bio has established collaborations with the University of Pennsylvania and The Regents of the University of California to further its research efforts.

Biodesy has developed a unique and highly sensitive means of detecting conformational change in proteins and other biological molecules. Our technology, based on a phenomenon called ‘second-harmonic generation’ (SHG), can monitor structural change at any site within a protein, in real time.

Akouos, Inc. is a biotechnology company that specializes in developing gene therapies aimed at restoring and preserving hearing for individuals with hearing loss. The company utilizes a proprietary platform that includes a library of adeno-associated viral vectors and innovative delivery methods. Its lead product candidate, AK-OTOF, targets hearing loss caused by mutations in the OTOF gene. Akouos is committed to addressing various forms of sensorineural hearing loss, which can result from genetic mutations, ototoxic drug exposure, and aging. Founded in 2016 and headquartered in Boston, Massachusetts, Akouos has formed strategic partnerships with organizations such as Massachusetts Eye and Ear and Lonza, Inc. to enhance its research and development efforts.

Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.

NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.

Precision Nanosystems develops tools and processes for the development and manufacture of nanoparticles for use as medicines and in medical research. It offers NanoAssemblr benchtop instrument for prototyping of nanoparticles, as well as for the development of nanoparticle-based drugs delivering RNA, small-molecule, and protein therapeutics. The company also provides Neuro9Kit for the study of gene function in neurons and glial cells, as well as potent delivery to primary cells; Test9Kit for the study of gene function in various cell types; and Hepato9Kit for the study of gene function in the liver. In addition, it provides instruments, reagents, and services to the life sciences researchers.

Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.

Escient Pharmaceuticals, Inc., a biotechnology company, develops and manufactures G protein-coupled receptor (GPCR)-targeted drugs for treating neuro-immuno-inflammatory and autoreactive diseases. The company focuses on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-Protein Receptors (Mrgprs) for neuro-immuno-inflammatory and autoreactive diseases. Escient Pharmaceuticals, Inc. was formerly known as Mas Therapeutics, Inc. The company was founded in 2017 and is based in San Diego, California.

Rallybio, LLC is a biopharmaceutical company based in New Haven, Connecticut, that focuses on developing innovative therapies for patients with severe and rare disorders. Founded in 2018, the company is dedicated to addressing life-threatening conditions, particularly through its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT). This rare disease can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's research emphasizes the development of antibody, small molecule, and engineered protein therapies, primarily in the late discovery to early clinical stages. Through its efforts, Rallybio seeks to transform the lives of patients suffering from devastating diseases.

Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company was founded in 2013 and is headquartered in Connecticut, United States.

Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.

Novome Biotechnologies, Inc. is a biotechnology company based in South San Francisco, California, that specializes in engineering bacteria from the human gut to address chronic diseases. Founded in 2015, the company has developed a platform for the controlled colonization of the gut with genetically engineered bacteria, known as Genetically Engineered Microbial Medicines (GEMMs). This innovative approach allows for sustained therapeutic interventions through the precise delivery of microbial activities. Novome's lead preclinical program targets hyperoxaluria by creating a therapeutic strain of bacteria aimed at degrading oxalate to help prevent kidney stone formation. The company is also expanding its synthetic biology platform to explore additional therapeutic applications.

Neurogastrx, Inc. is a venture-stage biopharmaceutical company focused on developing innovative therapies for gastrointestinal disorders. Established in 2017 and located in Campbell, California, the company aims to address the unmet medical needs associated with functional and motility disorders of the gastrointestinal tract. One of its key products, NG101, is designed to enhance gastric motility while also possessing antiemetic properties. Neurogastrx's specialty therapies target the enteric nervous system, addressing issues related to gut contractions, sensation, and the brain-gut axis, ultimately striving to alleviate the burden of these disorders on patients and the healthcare system.

Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.

Pear Therapeutics, Inc. focuses on developing and delivering clinically validated software-based therapeutics aimed at treating behavioral health disorders, including psychiatric and neurologic conditions. The company creates digital therapies for severe conditions such as addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and chronic insomnia. Its key products include mobile digital therapies that incentivize patients for completing treatment modules, reSET for substance use disorder, reSET-O for opioid use disorder, and Somryst for insomnia. Additionally, Pear Therapeutics offers PearConnect, a comprehensive patient services center that provides support for patients throughout their treatment journey, connects healthcare providers to resources, and assists insurance companies with claims processing. Founded in 2013, Pear Therapeutics is headquartered in Boston, Massachusetts, with an additional office in San Francisco, California.

Akouos, Inc. is a biotechnology company that specializes in developing gene therapies aimed at restoring and preserving hearing for individuals with hearing loss. The company utilizes a proprietary platform that includes a library of adeno-associated viral vectors and innovative delivery methods. Its lead product candidate, AK-OTOF, targets hearing loss caused by mutations in the OTOF gene. Akouos is committed to addressing various forms of sensorineural hearing loss, which can result from genetic mutations, ototoxic drug exposure, and aging. Founded in 2016 and headquartered in Boston, Massachusetts, Akouos has formed strategic partnerships with organizations such as Massachusetts Eye and Ear and Lonza, Inc. to enhance its research and development efforts.

Nouscom is a biotechnology company focused on developing innovative immunotherapy solutions for cancer treatment. Headquartered in Basel, Switzerland, with operations in Rome, Italy, the company specializes in engineered viral vector vaccines. Their platform is designed to express long strings of tumor neoantigens, facilitating the induction of strong antitumor T-cell responses to enhance cancer-specific cellular immunity. The leadership team, including experienced entrepreneurs like Prof. Riccardo Cortese, brings a wealth of expertise from previous successful ventures in the field of oncolytic and genetic vaccines.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, that specializes in the development of liquid and tissue biopsy analysis platforms aimed at the detection of rare cells. Founded in 2009, RareCyte focuses on providing innovative technologies for the Life Sciences research, drug development, and diagnostic markets. The company offers a range of products, including sample preparation systems, staining kits, and automated fluorescence microscopy instruments. Its AccuCyte system is particularly notable for enabling the unbiased discovery and isolation of circulating tumor cells and circulating endothelial cells from whole blood. RareCyte's technologies are designed to address complex challenges in cancer and cardiovascular disease research, facilitating advancements in precision medicine and non-invasive prenatal testing.

Scientist.com has connected buyers and sellers of research services. Through this exchange, they are able to deliver faster science through an innovative approach to R&D. Find the best resources to support studies surrounding human biological samples, biomarkers, immunotherapy, protein engineering, molecular pharmacology, in vitro / in vivo assays and over 3,000 additional areas.

Scientist.com has connected buyers and sellers of research services. Through this exchange, they are able to deliver faster science through an innovative approach to R&D. Find the best resources to support studies surrounding human biological samples, biomarkers, immunotherapy, protein engineering, molecular pharmacology, in vitro / in vivo assays and over 3,000 additional areas.

Kinestral Technologies, Inc. specializes in manufacturing smart-tinting glass, branded as Halio, for both commercial and residential applications. Halio glass can transition from clear to tinted or dark, either automatically or on command, enhancing architectural design by providing versatile solutions for windows, walls, and skylights. This technology offers significant advantages over traditional electrochromic glass, including faster tinting, uniform coloration, and a natural appearance. Kinestral also provides a range of supporting products, such as the Halio Tint Selector, which allows localized control of window tinting, and Halio Cloud, an interface for integrating window operations with building automation systems. Founded in 2010 and headquartered in Hayward, California, Kinestral has established a strategic partnership with Asahi Glass Co., Ltd. Its advanced manufacturing techniques ensure reliable production and timely delivery for projects worldwide, ultimately aiming to improve energy efficiency and comfort in indoor environments.

GenePeeks, Inc. is a genetic information company focused on helping families mitigate the risk of heritable diseases. Established in 2009 and based in New York, the company has developed a proprietary software platform that utilizes Next-Generation sequencing data to simulate the genetic recombination that occurs during human reproduction. By digitally weaving together the DNA of prospective parents, GenePeeks' technology generates analytic targets that represent tens of thousands of "virtual genomes," offering insights into the potential genetic profile of future children. This approach enables the identification of disease risks that are not detectable through existing pre-conception screening methods, providing valuable genetic insight for healthcare professionals and prospective parents.

scPharmaceticals is creating innovative and important new therapeutic options by administering drugs subcutaneously using a convenient two component delivery system suitable for patient self-administration.In February 2013 scPharmaceuticals was formed to continue the groundbreaking work of SpringLeaf Therapeutics, a Boston area company that started in 2007. scPharmaceuticals targets the untapped opportunity of treating patients with serious medical conditions with a convenient safe and comfortable subcutaneous administration of a drug. This is therapeutically equivalent to intravenous administration while avoiding the cost, burden and risks associated with intravenous administration.

Impel NeuroPharma is a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier(BBB) using direct nose-to-brain delivery. It is focused on developing transformative therapies that unlock the full potential of therapeutic molecules for people living with CNS disorders with high unmet medical needs. The company was founded in 2008 and is headquartered in Seattle, Washington.

Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.

Chrono Therapeutics Inc., a digital transdermal drug delivery company, develops SmartStop, a digital nicotine replacement therapy. Its wearable solution tailors the timing and dose sizes of drugs, preempts predictable peak disease, and addiction symptoms with a device. The company was incorporated in 2003 and is based in Hayward, California.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.

Purigen Biosystems' innovative products offer a truly transformative solution for DNA and RNA purification. Our proprietary approach uses isotachophoresis to separate nucleic acids freely in solution without binding or stripping from a physical surface. Because of this, our technology is agnostic to nucleic acid size or sequence and delivers unbiased results ― even from the more challenging sample types like FFPE tissue or low cell counts. Our Ionic Purification System and Kits combine to provide researchers with a fast, efficient and effective alternative for automated nucleic acid purification.

IDEAYA Biosciences is an oncology-focused biotechnology company based in South San Francisco, California, dedicated to the discovery and development of targeted therapeutics for genetically defined patient populations. The company specializes in precision medicine using molecular diagnostics and synthetic lethality approaches to address cancer treatment. Its lead product candidate, IDE196, is a protein kinase C inhibitor currently undergoing Phase 1/2 clinical trials for cancers associated with GNAQ or GNA11 gene mutations. IDEAYA's preclinical pipeline includes programs targeting various mechanisms related to DNA damage and repair, such as MAT2A for tumors with MTAP deletions, Pol-theta for homologous recombination deficiency, and PARG for BRCA2 mutation context. The company collaborates with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase, while also engaging in partnerships for clinical trials with Pfizer and GlaxoSmithKline. Founded in 2015, IDEAYA aims to advance innovative therapies for enhancing immunotherapy responses and improving patient outcomes in oncology.

Homology Medicines, Inc. is a genetic medicines company based in Bedford, Massachusetts, focused on improving the lives of patients with rare genetic diseases. The company employs a proprietary platform that utilizes human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to deliver genetic therapies in vivo, either through gene therapy or nuclease-free gene editing. This innovative approach allows for targeted treatment of various disease-relevant tissues, including the liver and central nervous system, through a single injection. Homology's lead product candidate, HMI-102, is currently in a Phase 1/2 clinical trial for treating phenylketonuria (PKU) in adults, while HMI-103 targets pediatric PKU patients, and HMI-202 is being developed for metachromatic leukodystrophy. Founded in 2015, Homology Medicines aims to address significant unmet medical needs by targeting the underlying causes of genetic disorders.

Aprea Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing cancer therapeutics that target the mutant p53 tumor suppressor protein. The lead product candidate, APR-246, is a first-in-class small molecule p53 reactivator currently in late-stage clinical development for hematologic malignancies, specifically myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006 and headquartered in Boston, Massachusetts, Aprea aims to address significant unmet medical needs in cancer treatment through innovative therapies. The company is primarily backed by KDev Investments AB and other stakeholders, including Östersjöstiftelsen and Praktikerinvest, reflecting a strong investment foundation for its research and development efforts.

Pear Therapeutics, Inc. focuses on developing and delivering clinically validated software-based therapeutics aimed at treating behavioral health disorders, including psychiatric and neurologic conditions. The company creates digital therapies for severe conditions such as addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and chronic insomnia. Its key products include mobile digital therapies that incentivize patients for completing treatment modules, reSET for substance use disorder, reSET-O for opioid use disorder, and Somryst for insomnia. Additionally, Pear Therapeutics offers PearConnect, a comprehensive patient services center that provides support for patients throughout their treatment journey, connects healthcare providers to resources, and assists insurance companies with claims processing. Founded in 2013, Pear Therapeutics is headquartered in Boston, Massachusetts, with an additional office in San Francisco, California.

Biodesy has developed a unique and highly sensitive means of detecting conformational change in proteins and other biological molecules. Our technology, based on a phenomenon called ‘second-harmonic generation’ (SHG), can monitor structural change at any site within a protein, in real time.

Atterocor, Inc. focuses on research and development of therapeutics for adrenal disease. Atterocor, Inc. was incorporated in 2012 and is based in Ann Arbor, Michigan.

Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.

Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company was founded in 2013 and is headquartered in Connecticut, United States.

Portal Instruments, Inc. is a clinical-stage medical device company based in Cambridge, Massachusetts, specializing in needle-free jet injectors for drug delivery. Founded in 2012, the company develops innovative technology that allows for the precise administration of medications through the skin without the use of needles. This platform is designed to accommodate various drug viscosities and concentrations, enhancing compatibility with pharmaceutical manufacturing processes. The jet injectors deliver medication via a narrow stream, ensuring a painless and silent experience for patients. Portal Instruments aims to replace traditional needles and syringes with its advanced delivery mechanism, making it applicable across multiple fields, including medical, agricultural, and cosmetic applications. The company is positioned to transform the drug delivery landscape and improve patient experiences for those managing chronic diseases.

Precision Nanosystems develops tools and processes for the development and manufacture of nanoparticles for use as medicines and in medical research. It offers NanoAssemblr benchtop instrument for prototyping of nanoparticles, as well as for the development of nanoparticle-based drugs delivering RNA, small-molecule, and protein therapeutics. The company also provides Neuro9Kit for the study of gene function in neurons and glial cells, as well as potent delivery to primary cells; Test9Kit for the study of gene function in various cell types; and Hepato9Kit for the study of gene function in the liver. In addition, it provides instruments, reagents, and services to the life sciences researchers.

Calibrium is an emerging privately held biopharmaceutical company focused on developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases. Calibrium was co-founded by Fritz French, Calibrium’s Chief Executive Officer, and Richard DiMarchi, PhD, Calibirum’s Chief Scientific Officer.

Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company was founded in 2003 and is based in Lexington, Massachusetts.

Viveve is a women's sexual health company that develops non-surgical treatment for women's sexual health. It focuses on developing a Viveve procedure, a non-surgical treatment for women who have experienced vaginal looseness and loss of physical sensation that is common to women after vaginal childbirth. The company’s Viveve System is a radiofrequency device that uses low levels of energy to restore collagen fibers overstretched and damaged during vaginal childbirth. Viveve, Inc. was formerly known as TiVaMed, Inc. and changed its name to Viveve, Inc. in November 2009. The company was founded in 2005 and is based in Palo Alto, California.

Spyryx Biosciences is a biopharmaceutical company based in Durham, North Carolina, specializing in the development of inhaled peptide therapeutics aimed at treating obstructive lung diseases, specifically cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Founded in 2013 by Dr. Robert Tarran, the company emerged from his discovery of a novel mechanism by which the lungs regulate surface fluid. This mechanism is impaired in CF patients due to genetic mutations, leading to dehydration, mucus buildup, and subsequent lung damage. Spyryx's therapeutic approach targets this underlying dysfunction, showing promising results in preclinical studies by significantly improving survival in animal models of CF. Importantly, the treatment is designed to function independently of the specific genetic mutations responsible for CF, offering potential benefits to a broader patient population. Additionally, the company is exploring the relevance of this fluid regulation mechanism in COPD, a condition characterized by chronic bronchitis and emphysema, as part of its commitment to addressing multiple obstructive lung diseases.

Pear Therapeutics, Inc. focuses on developing and delivering clinically validated software-based therapeutics aimed at treating behavioral health disorders, including psychiatric and neurologic conditions. The company creates digital therapies for severe conditions such as addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and chronic insomnia. Its key products include mobile digital therapies that incentivize patients for completing treatment modules, reSET for substance use disorder, reSET-O for opioid use disorder, and Somryst for insomnia. Additionally, Pear Therapeutics offers PearConnect, a comprehensive patient services center that provides support for patients throughout their treatment journey, connects healthcare providers to resources, and assists insurance companies with claims processing. Founded in 2013, Pear Therapeutics is headquartered in Boston, Massachusetts, with an additional office in San Francisco, California.

Cidara Therapeutics is a biotechnology company based in San Diego, California, dedicated to the discovery, development, and commercialization of innovative anti-infective therapies. The company's lead product candidate, rezafungin acetate, is an antifungal agent from the echinocandin class designed to treat and prevent serious invasive fungal infections, such as candidemia and invasive candidiasis, which carry high mortality rates. In addition to its antifungal efforts, Cidara is advancing its Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating viral infections, including influenza, RSV, HIV, and coronaviruses. Founded in 2012, Cidara Therapeutics has positioned itself as a key player in addressing life-threatening illnesses, particularly those that pose challenges due to immune system deficiencies.

IDEAYA Biosciences is an oncology-focused biotechnology company based in South San Francisco, California, dedicated to the discovery and development of targeted therapeutics for genetically defined patient populations. The company specializes in precision medicine using molecular diagnostics and synthetic lethality approaches to address cancer treatment. Its lead product candidate, IDE196, is a protein kinase C inhibitor currently undergoing Phase 1/2 clinical trials for cancers associated with GNAQ or GNA11 gene mutations. IDEAYA's preclinical pipeline includes programs targeting various mechanisms related to DNA damage and repair, such as MAT2A for tumors with MTAP deletions, Pol-theta for homologous recombination deficiency, and PARG for BRCA2 mutation context. The company collaborates with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase, while also engaging in partnerships for clinical trials with Pfizer and GlaxoSmithKline. Founded in 2015, IDEAYA aims to advance innovative therapies for enhancing immunotherapy responses and improving patient outcomes in oncology.

Audentes Therapeutics is a clinical-stage biotechnology company dedicated to developing and commercializing gene therapy products for patients with serious, life-threatening rare diseases caused by single gene defects. The company is advancing several therapies, including AT132, currently in Phase I/II clinical trials for X-linked myotubular myopathy, and AT342, also in Phase I/II studies for Crigler-Najjar syndrome. Additionally, Audentes is exploring AT845 in preclinical studies for Pompe disease and AT307 for the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. The company is also working on vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. Collaborations include a partnership with Genethon for XLMTM treatments and an agreement with the University of Pennsylvania for Crigler-Najjar syndrome products. Founded in 2012 and headquartered in San Francisco, California, Audentes Therapeutics operates as a subsidiary of Astellas US Holding, Inc.

Cidara Therapeutics is a biotechnology company based in San Diego, California, dedicated to the discovery, development, and commercialization of innovative anti-infective therapies. The company's lead product candidate, rezafungin acetate, is an antifungal agent from the echinocandin class designed to treat and prevent serious invasive fungal infections, such as candidemia and invasive candidiasis, which carry high mortality rates. In addition to its antifungal efforts, Cidara is advancing its Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating viral infections, including influenza, RSV, HIV, and coronaviruses. Founded in 2012, Cidara Therapeutics has positioned itself as a key player in addressing life-threatening illnesses, particularly those that pose challenges due to immune system deficiencies.

Chrono Therapeutics Inc., a digital transdermal drug delivery company, develops SmartStop, a digital nicotine replacement therapy. Its wearable solution tailors the timing and dose sizes of drugs, preempts predictable peak disease, and addiction symptoms with a device. The company was incorporated in 2003 and is based in Hayward, California.

Ceterix Orthopaedics, Inc. develops novel surgical tools for arthroscopic procedures. The Ceterix technology enables surgeons to place stitches in very tight joint compartments, while protecting sensitive surrounding structures such as nerves, arteries and cartilage. This technology has applications in numerous arthroscopic procedures in knees, hips and shoulders. Ceterix was established in October 2010. The company was founded based on the inventions of Dr. Justin Saliman, an orthopaedic surgeon specializing in sports medicine. Dr. Saliman envisioned improving the outcomes of arthroscopic procedures by enabling surgeons to place suture patterns that today can be done only in open procedures, if at all. Ceterix is based in Menlo Park, California.

EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.

Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators.

scPharmaceticals is creating innovative and important new therapeutic options by administering drugs subcutaneously using a convenient two component delivery system suitable for patient self-administration.In February 2013 scPharmaceuticals was formed to continue the groundbreaking work of SpringLeaf Therapeutics, a Boston area company that started in 2007. scPharmaceuticals targets the untapped opportunity of treating patients with serious medical conditions with a convenient safe and comfortable subcutaneous administration of a drug. This is therapeutically equivalent to intravenous administration while avoiding the cost, burden and risks associated with intravenous administration.

Igenica, Inc. is a biotherapeutic company based in Burlingame, California, specializing in the discovery and development of antibodies and antibody-drug conjugates for cancer treatment. The company is dedicated to advancing immunotherapies and functional antibodies that target tumors, as well as creating antibody-drug conjugates. Igenica's key products include IGN523, a humanized monoclonal antibody aimed at various hematologic and solid tumors; IGN786, an antibody-drug conjugate; and IGN381, which targets immune checkpoints in the tumor microenvironment. Founded in 2008, Igenica operates with a strategic oncology research agreement with MedImmune and is backed by prominent life science investors. The leadership team at Igenica has significant experience in antibody drug discovery and has contributed to the development of multiple approved antibody therapeutic products.

Bellerophon Therapeutics LLC is a clinical stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Two of the company's product candidates are based on its proprietary pulsatile nitric oxide delivery device, INOpulse®, and are in Phase 2 clinical trials – one for the treatment of PAH and a second for the treatment of PH-COPD. The company's third product candidate, bioabsorbable cardiac matrix (BCM), is an injectable device currently undergoing a feasibility clinical trial, which is a CE mark registration trial in the European Union and is comparable to a Phase 2 trial in U.S. drug development, for the prevention of cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction (heart attack).

Biodesy has developed a unique and highly sensitive means of detecting conformational change in proteins and other biological molecules. Our technology, based on a phenomenon called ‘second-harmonic generation’ (SHG), can monitor structural change at any site within a protein, in real time.

Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company was founded in 2013 and is headquartered in Connecticut, United States.

Audentes Therapeutics is a clinical-stage biotechnology company dedicated to developing and commercializing gene therapy products for patients with serious, life-threatening rare diseases caused by single gene defects. The company is advancing several therapies, including AT132, currently in Phase I/II clinical trials for X-linked myotubular myopathy, and AT342, also in Phase I/II studies for Crigler-Najjar syndrome. Additionally, Audentes is exploring AT845 in preclinical studies for Pompe disease and AT307 for the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. The company is also working on vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. Collaborations include a partnership with Genethon for XLMTM treatments and an agreement with the University of Pennsylvania for Crigler-Najjar syndrome products. Founded in 2012 and headquartered in San Francisco, California, Audentes Therapeutics operates as a subsidiary of Astellas US Holding, Inc.

Pearl Therapeutics is a private company focused on developing dual and triple combination therapies for prevalent respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), asthma, and rhinosinusitis. The company aims to enhance patient care by providing advanced inhaled therapies through familiar metered dose inhalers. Led by an experienced team specializing in respiratory product development, Pearl Therapeutics is dedicated to creating alternatives that improve safety and efficacy compared to existing treatments, ultimately striving for better clinical outcomes for patients and healthcare providers.

Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.

Achaogen, Inc. is a biopharmaceutical company focused on developing antibacterial agents to combat multi-drug resistant (MDR) gram-negative infections. The company's primary product, plazomicin, is designed to treat serious bacterial infections caused by MDR enterobacteriaceae, particularly carbapenem-resistant strains. Additionally, Achaogen is working on C-Scape, an orally-administered combination therapy targeting infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established several collaboration agreements, including partnerships with Thermo Fisher Scientific for assay development, and Ionis Pharmaceuticals for the advancement of aminoglycoside antibacterial compounds. The company generates revenue primarily through government contracts for research and development. Founded in 2002 and based in South San Francisco, California, Achaogen filed for Chapter 11 bankruptcy in April 2019, transitioning to a liquidation plan in May 2020.

Flexion Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for musculoskeletal conditions. Based in Burlington, Massachusetts, it offers ZILRETTA, an intra-articular injection specifically designed for managing osteoarthritis pain in the knee. The company is also developing FX201, a gene therapy aimed at promoting the production of an anti-inflammatory protein for knee osteoarthritis pain relief, and FX301, a NaV1.7 inhibitor intended for post-operative pain management. Since its founding in 2007, Flexion Therapeutics has collaborated with pharmaceutical and biotechnology firms to advance its drug candidates through clinical trials, thereby enhancing the therapeutic portfolios of its partners.

Pearl Therapeutics is a private company focused on developing dual and triple combination therapies for prevalent respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), asthma, and rhinosinusitis. The company aims to enhance patient care by providing advanced inhaled therapies through familiar metered dose inhalers. Led by an experienced team specializing in respiratory product development, Pearl Therapeutics is dedicated to creating alternatives that improve safety and efficacy compared to existing treatments, ultimately striving for better clinical outcomes for patients and healthcare providers.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, that specializes in developing and commercializing innovative therapies for iron deficiency, nephrology, and cardio-renal conditions. The company's primary product is VELTASSA, a potassium binder used for treating hyperkalemia. Relypsa focuses on creating novel non-absorbed polymeric drugs aimed at addressing significant medical needs in cardiovascular and renal diseases. Established in 2007, Relypsa is committed to advancing its proprietary polymer platform to discover and develop additional therapeutic candidates. As of August 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

Pearl Therapeutics is a private company focused on developing dual and triple combination therapies for prevalent respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), asthma, and rhinosinusitis. The company aims to enhance patient care by providing advanced inhaled therapies through familiar metered dose inhalers. Led by an experienced team specializing in respiratory product development, Pearl Therapeutics is dedicated to creating alternatives that improve safety and efficacy compared to existing treatments, ultimately striving for better clinical outcomes for patients and healthcare providers.